MPS Ltd Approves FY26 Audited Results, No Final Dividend

MPS Ltd's Board of Directors approved the audited financial results for Q4 and the financial year ended March 31, 2026. Walker Chandiok & Co LLP issued an unmodified opinion on the results. The board decided not to recommend a final dividend for FY26, retaining capital for growth following the acquisition of Unbound Medicine, Inc. The board also approved the appointment of KPMG as internal auditors for MPS Ltd and its material subsidiary for three years starting FY27 and re-appointed Walker Chandiok & Co LLP as statutory auditors for a second term of five years, subject to shareholder approval.